Antonio Manuel Lax Pérez

Pascual-Figal D, Lax A, Asensio Lopez MC. Circulating ST2, from biomarker to pathogenic mediator. Rev Esp Cardiol (Engl Ed). 2023 Sep;76(9):672-674. doi: 10.1016/j.rec.2023.02.012. Epub 2023 Apr 19. No abstract available. English, Spanish. PubMed PMID: 37085116.

AÑO: 2023; IF: 5.9

37085116

Sanchez-Camara S, Asensio-Lopez MC, Royo-Villanova M, Soler F, Jara-Rubio R, Garrido-Penalver JF, Pinar E, Hernandez-Vicente A, Hurtado JA, Lax A, Pascual-Figal DA. Critical warm ischemia time point for cardiac donation after circulatory death. Am J Transplant. 2022 May;22(5):1321-1328. doi: 10.1111/ajt.16987. Epub 2022 Feb 21. PubMed PMID: 35114047; PubMed Central PMCID: PMC9303247.

AÑO: 2022; IF: 8.8

35114047

Asensio-Lopez MC, Sassi Y, Soler F, Fernandez Del Palacio MJ, Pascual-Figal D, Lax A. The miRNA199a/SIRT1/P300/Yy1/sST2 signaling axis regulates adverse cardiac remodeling following MI. Sci Rep. 2021 Feb 16;11(1):3915. doi: 10.1038/s41598-021-82745-9. PubMed PMID: 33594087; PubMed Central PMCID: PMC7887255.

AÑO: 2021; IF: 4.996

33594087

Asensio Lopez MDC, Lax A, Hernandez Vicente A, Saura Guillen E, Hernandez-Martinez A, Fernandez Del Palacio MJ, Bayes-Genis A, Pascual Figal DA. Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Sci Rep. 2020 Aug 11;10(1):13553. doi: 10.1038/s41598-020-70454-8. Erratum in: Sci Rep. 2020 Oct 9;10(1):17266. PubMed PMID: 32782412; PubMed Central PMCID: PMC7419540.

AÑO: 2020; IF: 4.379

32782412

Del Carmen Asensio Lopez M, Lax A, Hernandez Vicente A, Saura Guillen E, Hernandez-Martinez A, Fernandez Del Palacio MJ, Bayes-Genis A, Pascual Figal DA. Author Correction: Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Sci Rep. 2020 Oct 9;10(1):17266. doi: 10.1038/s41598-020-73065-5. PubMed PMID: 33037250; PubMed Central PMCID: PMC7547718.

AÑO: 2020; IF: 4.379

33037250